Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:ARVNNASDAQ:TSHANASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.11+3.3%$1.16$0.87▼$6.78$110.49M0.76833,934 shs1.33 million shsARVNArvinas$6.26+3.1%$7.73$5.90▼$37.38$456.92M2.211.32 million shs2.11 million shsTSHATaysha Gene Therapies$2.56+8.0%$1.70$1.05▼$4.32$524.94M0.92.83 million shs6.65 million shsURGNUroGen Pharma$9.85-0.2%$10.66$8.94▼$20.70$454.15M0.66547,508 shs845,415 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-3.60%+4.39%+9.09%-35.93%-79.92%ARVNArvinas-3.50%-8.52%-17.97%-65.65%-80.64%TSHATaysha Gene Therapies+1.28%+24.41%+85.16%+46.30%-7.78%URGNUroGen Pharma-2.66%-2.50%-6.89%-6.36%-23.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.6266 of 5 stars3.12.00.04.51.81.70.6ARVNArvinas3.5413 of 5 stars4.33.00.00.01.82.51.3TSHATaysha Gene Therapies1.9433 of 5 stars3.50.00.00.02.11.71.3URGNUroGen Pharma4.3651 of 5 stars4.52.00.04.53.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00261.99% UpsideARVNArvinas 2.60Moderate Buy$20.92234.13% UpsideTSHATaysha Gene Therapies 3.00Buy$6.43151.12% UpsideURGNUroGen Pharma 3.00Buy$32.86233.58% UpsideCurrent Analyst Ratings BreakdownLatest ALEC, URGN, ARVN, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ARVNArvinasUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $21.005/13/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.005/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.005/9/2025ARVNArvinasMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.005/8/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/5/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.505/5/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.005/5/2025ARVNArvinasTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$21.00 ➝ $11.005/2/2025ARVNArvinasBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$16.005/2/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$26.00 ➝ $19.005/2/2025ARVNArvinasThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $8.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$88.34M1.25N/AN/A$1.41 per share0.78ARVNArvinas$426.90M1.07N/AN/A$8.17 per share0.77TSHATaysha Gene Therapies$8.33M63.00N/AN/A$0.40 per share6.40URGNUroGen Pharma$90.40M5.02N/AN/A($2.78) per share-3.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$130.39M-$1.23N/AN/AN/A-257.54%-108.77%-27.03%N/AARVNArvinas-$198.90M-$0.66N/AN/AN/A-75.51%-33.75%-16.75%7/29/2025 (Estimated)TSHATaysha Gene Therapies-$111.57M-$0.364.06N/AN/A-229.67%-106.36%-49.16%5/15/2025 (Estimated)URGNUroGen Pharma-$102.24M-$3.23N/AN/AN/A-129.11%N/A-47.94%N/ALatest ALEC, URGN, ARVN, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million5/12/2025Q1 2025URGNUroGen Pharma-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million5/1/2025Q1 2025ARVNArvinas-$0.93$1.14+$2.07$1.14$41.87 millionN/A3/10/2025Q4 2024URGNUroGen Pharma-$0.69-$0.80-$0.11-$0.80$25.25 million$24.57 million2/26/2025Q4 2024ALECAlector-$0.61-$0.02+$0.59-$0.02$20.41 million$54.24 million2/26/2025Q4 2024TSHATaysha Gene Therapies-$0.08-$0.07+$0.01-$0.07$2.05 million$2.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlectorN/A3.293.29ARVNArvinasN/A4.644.64TSHATaysha Gene Therapies0.485.515.51URGNUroGen Pharma4.779.008.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%ARVNArvinas95.19%TSHATaysha Gene Therapies77.70%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%ARVNArvinas4.73%TSHATaysha Gene Therapies2.70%URGNUroGen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million89.02 millionOptionableARVNArvinas42072.99 million65.18 millionOptionableTSHATaysha Gene Therapies180205.06 million199.41 millionOptionableURGNUroGen Pharma20046.11 million22.26 millionOptionableALEC, URGN, ARVN, and TSHA HeadlinesRecent News About These CompaniesHC Wainwright Reaffirms Buy Rating for UroGen Pharma (NASDAQ:URGN)May 15 at 8:19 AM | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Reported Earnings, And Analysts Cut Their Target PriceMay 15 at 8:07 AM | finance.yahoo.comUroGen Pharma (NASDAQ:URGN) Shares Gap Down After Earnings MissMay 14 at 12:49 PM | marketbeat.comUroGen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Expectations By $0.09 EPSMay 14 at 8:47 AM | marketbeat.comEarnings call transcript: UroGen Pharma Q1 2025 reveals revenue miss, stock edges upMay 14 at 4:16 AM | uk.investing.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2025 Earnings Call TranscriptMay 13 at 6:15 PM | msn.comUroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ...May 13 at 5:28 AM | finance.yahoo.comUroGen Pharma (NASDAQ:URGN) Shares Gap Down Following Weak EarningsMay 13 at 1:13 AM | americanbankingnews.comUroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call TranscriptMay 12 at 2:01 PM | seekingalpha.comUrogen Pharma (URGN) Reports Q1 Loss, Lags Revenue EstimatesMay 12 at 10:15 AM | zacks.comUroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business UpdateMay 12 at 8:59 AM | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Position Reduced by Schonfeld Strategic Advisors LLCMay 12 at 3:53 AM | marketbeat.comD. Boral Capital Reaffirms "Buy" Rating for UroGen Pharma (NASDAQ:URGN)May 10, 2025 | marketbeat.comDAFNA Capital Management LLC Increases Position in UroGen Pharma Ltd. (NASDAQ:URGN)May 10, 2025 | marketbeat.comA Look at UroGen Pharma's Upcoming Earnings ReportMay 9, 2025 | benzinga.comUroGen Pharma Q1 Earnings PreviewMay 9, 2025 | msn.comUroGen's bladder cancer treatment to be reviewed by FDA advisory committeeMay 7, 2025 | msn.comUroGen Pharma (URGN) Expected to Announce Earnings on MondayMay 7, 2025 | marketbeat.comCantor Fitzgerald L. P. Takes $3.79 Million Position in UroGen Pharma Ltd. (NASDAQ:URGN)May 7, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Shares Bought by Price T Rowe Associates Inc. MDMay 7, 2025 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by JPMorgan Chase & Co.May 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALEC, URGN, ARVN, and TSHA Company DescriptionsAlector NASDAQ:ALEC$1.10 +0.04 (+3.27%) As of 04:00 PM EasternAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Arvinas NASDAQ:ARVN$6.26 +0.19 (+3.13%) As of 04:00 PM EasternArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Taysha Gene Therapies NASDAQ:TSHA$2.56 +0.19 (+8.02%) As of 04:00 PM EasternTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.UroGen Pharma NASDAQ:URGN$9.85 -0.02 (-0.20%) As of 04:00 PM EasternUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
